www.fdanews.com/articles/85255-alexion-announces-results-of-primo-cabg2-trial
ALEXION ANNOUNCES RESULTS OF PRIMO-CABG2 TRIAL
March 14, 2006
Alexion Pharmaceuticals has reported results from its Phase III PRIMO-CABG2 clinical trial with pexelizumab. The study revealed that the drug reduced the primary endpoint, but did not achieve statistical significance for the co-primary endpoint of death or myocardial infarction through POD 30.
Pexelizumab, a terminal complement inhibitor, is a monoclonal antibody fragment that inhibits complement-mediated tissue damage. The trial enrolled moderate-to-high risk coronary artery bypass graft surgery patients. According to the company, pexelizumab appeared to be well-tolerated with an adverse event profile comparable to placebo.